Abstract
Twenty consecutive patients with a confirmed diagnosis of diffuse malignant mesothelioma of the pleura or peritoneum, previously untreated with chemotherapy, were studied in a Phase II trial of single‐agent 5‐fluorouracil. One partial response of 24 months was seen. Eleven patients were treated with single‐agent Adriamycin (doxorubicin) after progression on 5‐fluorouracil, and one partial response of 34 months was seen. It is concluded that 5‐fluorouracil has only minimal activity in diffuse malignant mesothelioma. Preliminary data suggest that Adriamycin has little activity as a second‐line agent. Copyright © 1984 American Cancer Society
Cite
CITATION STYLE
Harvey, V. J., Slevin, M. L., Ponder, B. A. J., Blackshaw, A. J., & Wrigley, P. F. M. (1984). Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single‐agent 5‐fluorouracil and adriamycin. Cancer, 54(6), 961–964. https://doi.org/10.1002/1097-0142(19840915)54:6<961::AID-CNCR2820540602>3.0.CO;2-B
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
